Clinical trials: Maintenance Therapy
Metabolism and Nutrition Disorder, Obesity
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have…
- Trial name
- NCT00781937
- Testing
- liraglutide
- Where
- 37 sites in United States, Canada
- Volunteers
- 422 people
- Sponsor
- Novo Nordisk A/S
Malignant Mesothelioma
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or observation works in…
- Trial name
- NCT01085630
- Testing
- pemetrexed disodium, clinical observation
- Where
- 145 sites in United States
- Volunteers
- 72 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pulmonary Disease, Chronic Obstructive
Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Open-label comparative multicentric cohort study in COPD patients with LABA/ICS, switched to either tiotropium/olodaterol and observed for 12 weeks approximately.
- Trial name
- NCT03954132
- Testing
- Spiolto® Respimat®, Triple-Therapy (LAMA/LABA/ICS)
- Where
- 75 sites in Germany
- Volunteers
- 469 people
- Sponsor
- Boehringer Ingelheim
Treatment Resistant Depression (TRD)
Maintenance TMS in Treatment Resistant Depression
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use.
- Trial name
- NCT06682299
- Testing
- Transmagnetic Stimulation, Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Austin Messner
Ulcerative Colitis
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis
- Trial name
- NCT04205643
- Testing
- CT-P13 SC (Infliximab)
- Where
- Poland
- Volunteers
- 548 people
- Sponsor
- Celltrion
Gastroesophageal Reflux Disease, Erosive Esophagitis
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
The purpose of this study is to assess the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents with erosive esophagitis (EE) and for maintenance of…
- Trial name
- NCT01642615
- Testing
- Dexlansoprazole
- Where
- 60 sites in United States, Belgium and 6 more
- Volunteers
- 63 people
- Sponsor
- Takeda
Psoriasis
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- LIMMITLESS (NCT03047395)
- Testing
- risankizumab
- Where
- 233 sites in United States, Australia and 15 more
- Volunteers
- 2,170 people
- Sponsor
- AbbVie
Diabetes Mellitus, Type 2, Insomnia
A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia
Objective - Type 2 uncontrolled diabetic patients often have low endogenous melatonin and suffer from sleep disorders. The effect of a prolonged-release melatonin (PRM) formulation on glucose lipid metabolism and sleep is studied…
- Trial name
- NCT00869128
- Testing
- Circadin
- Volunteers
- 36 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Obesity, Overweight
FitLink: Improving Weight Loss Maintenance by Using Digital Data to Provide Support and Accountability
Most adults in the U.S. are overweight or obese and find maintenance of weight loss difficult. This study is designed to aid in the development of a lifestyle modification program that can facilitate weight loss maintenance…
- Conditions
- Obesity, Overweight, Overweight and Obesity, Weight Loss
- Trial name
- NCT03337139
- Testing
- Gold Standard Behavior Therapy for Weight Loss, Standard Remote Behavior Therapy for Weight Loss, Digital Data Sharing Behavior Therapy for Weight Loss
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Drexel University
Primary Insomnia
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
This was a cross-over, polysomnography (PSG) study to test the safety, tolerability and effectiveness of different doses of MK-6096 in the treatment of participants with primary insomnia.
- Trial name
- NCT01021852
- Testing
- MK-6096
- Volunteers
- 326 people
- Sponsor
- Merck Sharp & Dohme LLC
Stage IV Non-small Cell Lung Cancer
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous…
- Trial name
- NCT03559049
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097629
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,020 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if guanfacine extended release is able to improve nighttime sleep in children with ADHD - associated insomnia while improving daytime ADHD…
- Conditions
- Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
- Trial name
- NCT01156051
- Testing
- Guanfacine extended-release tablets
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Children's Specialized Hospital
Delirium, Sleep Fragmentation
Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones
This study seeks to examine the effects of overnight noise reduction in critically ill patients who are receiving mechanical ventilation.
- Trial name
- NCT01343095
- Testing
- Foam Earplugs, Noise Canceling Headphones
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Wake Forest University
Plaque Psoriasis
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT01708629)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 157 sites in United States, Australia and 9 more
- Volunteers
- 1,881 people
- Sponsor
- Bausch Health Americas, Inc.
Insomnia, Metabolic Health
Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia
The aim of this study is to determine if suvorexant can help treat the severity of insomnia and improve metabolic health in midlife women who had both insomnia and indicators of metabolic syndrome.
- Conditions
- Insomnia, Metabolic Health, Menopause
- Trial name
- NCT05593653
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Brigham and Women's Hospital
Insomnia Disorder
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
- Trial name
- NCT02841709
- Testing
- ACT-541468
- Where
- 10 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Ovarian Cancer, Fallopian Tube Cancer
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
This study will be performed in women with platinum-sensitive, high-grade serous, high-grade endometrioid, undifferentiated epithelial ovarian cancer, carcinosarcoma, fallopian tube or primary peritoneal cancer (proven by central…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- EUDARIO (NCT03783949)
- Testing
- Ganetespib, Niraparib, Carboplatin
- Where
- 13 sites in Austria, Belgium and 3 more
- Volunteers
- 122 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Lymphocytic Leukemia, Chronic
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-line induction treatment with…
- Trial name
- NCT00718549
- Testing
- Cladribine, Cyclophosphamide, Rituximab
- Where
- 6 sites in Belarus, Poland
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Safety and Tolerability of Risperidone Implants
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
- Trial name
- NCT02773576
- Testing
- Risperidone implant
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Braeburn Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.